Advancements in PRRT for Neuroendocrine Tumors

This chapter examines the ongoing trials of alpha Peptide Receptor Radionuclide Therapy (PRRT), focusing on a promising compound called VMT and comparing alpha and beta therapies. It discusses the role of PRRT in treating neuroendocrine tumors, weighing efficacy against potential risks like kidney toxicity and complications such as myelodysplastic syndrome. Additionally, the chapter highlights the importance of personalized treatment strategies and the nuances of exploratory surgery in managing small bowel neuroendocrine tumors.